Advertisement
Advertisement
Trending on BioPharm International
1
Immatics’ PRAME-Targeted TCR Bispecific IMA402 Shows 32% Response Rate in PRAME-High Tumors
2
AAPS 2026 PharmSci 360 Video Recap: AI Transparency, Oral Peptides, and New Models
3
Lonza Adds Bioconjugation Suites in Visp to Meet Rising ADC Demand
4
Aclaris’ TSLP/IL-4Rα Bispecific ATI-052 Shows Early Activity in Atopic Dermatitis and Asthma
5

